Literature DB >> 19280234

Nationwide surveillance of antimicrobial resistance among Haemophilus influenzae and Streptococcus pneumoniae in intensive care units in Taiwan.

S-S Jean1, P-R Hsueh, W-S Lee, H-T Chang, M-Y Chou, I-S Chen, J-H Wang, C-F Lin, J-M Shyr, W-C Ko, J-J Wu, Y-C Liu, W-K Huang, L-J Teng, C-Y Liu.   

Abstract

A nationwide susceptibility surveillance of Streptococcus pneumoniae and Haemophilus influenzae isolates collected from patients treated at the intensive care units (ICUs) of ten Taiwanese major teaching hospitals was conducted from September 2005 through November 2005. High rates of resistance (intermediate/resistant) of S. pneumoniae to penicillin (85% resistance), ceftriaxone (46%/20%), and cefepime (43%/15%) by meningitis criteria, and in contrast, non-susceptibilities (intermediate/resistant) to penicillin (0%/0%), ceftriaxone (20%/0%) and cefepime (15%/0%) by non-meningitis criteria were noted (p values < 0.05) by the Clinical and Laboratory Standards Institute 2008. Resistant rate of S. pneumoniae to azithromycin was also high (63%). S. pneumoniae isolates were significantly more susceptible to ertapenem (87%) than to imipenem (39%) and meropenem (44%) (p values < 0.05). Rates of non-susceptibilities of H. influenzae isolates to ampicillin and cefaclor were high (55% and 45%, respectively). No beta-lactamase-negative ampicillin-resistant (BLNAR) H. influenzae isolates were found. Imipenem has a notably higher MIC(90) value (8 microg/ml) for H. influenzae than that of the other two carbapenems. Tigecycline showed good in vitro activities against these two respiratory pathogens. High rates of resistance among isolates of S. pneumoniae and H. influenzae continue to exist in the ICUs of Taiwan.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19280234     DOI: 10.1007/s10096-009-0727-3

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  8 in total

1.  Multicenter surveillance of antimicrobial resistance of major bacterial pathogens in intensive care units in 2000 in Taiwan.

Authors:  P R Hsueh; Y C Liu; D Yang; J J Yan; T L Wu; W K Huang; J J Wu; W C Ko; H S Leu; C R Yu; K T Luh
Journal:  Microb Drug Resist       Date:  2001       Impact factor: 3.431

2.  Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States.

Authors:  C G Whitney; M M Farley; J Hadler; L H Harrison; C Lexau; A Reingold; L Lefkowitz; P R Cieslak; M Cetron; E R Zell; J H Jorgensen; A Schuchat
Journal:  N Engl J Med       Date:  2000-12-28       Impact factor: 91.245

3.  In vitro activity of ertapenem (MK-0826) against multi-drug resistant Streptococcus pneumoniae compared with 13 other antimicrobials.

Authors:  Nicholaus J Hilliard; Crystal N Johnson; Sarah H Armstrong; Stephanie Quarles; Ken B Waites
Journal:  Int J Antimicrob Agents       Date:  2002-08       Impact factor: 5.283

4.  Antibacterial effects of meropenem and imipenem against Haemophilus influenzae.

Authors:  E Yourassowsky; M P Van der Linden; F Crokaert
Journal:  Chemotherapy       Date:  1991       Impact factor: 2.544

5.  Comparison of in vitro activities of tigecycline with other antimicrobial agents against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in Taiwan.

Authors:  Yeu-Jun Lau; Po-Ren Hsueh; Yung-Ching Liu; Jainn-Ming Shyr; Wen-Kuei Huang; Lee-Jene Teng; Cheng-Yi Liu; Kwen-Tay Luh
Journal:  Microb Drug Resist       Date:  2006       Impact factor: 3.431

6.  Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans.

Authors:  D J Hardy; R N Swanson; R A Rode; K Marsh; N L Shipkowitz; J J Clement
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

7.  In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004).

Authors:  Daryl J Hoban; Samuel K Bouchillon; Brian M Johnson; Jack L Johnson; Michael J Dowzicky
Journal:  Diagn Microbiol Infect Dis       Date:  2005-07       Impact factor: 2.803

8.  First characterization of heterogeneous resistance to imipenem in invasive nontypeable Haemophilus influenzae isolates.

Authors:  Marina Cerquetti; Maria Giufrè; Rita Cardines; Paola Mastrantonio
Journal:  Antimicrob Agents Chemother       Date:  2007-07-09       Impact factor: 5.191

  8 in total
  4 in total

Review 1.  The role of fluoroquinolones in the management of urinary tract infections in areas with high rates of fluoroquinolone-resistant uropathogens.

Authors:  Y-H Chen; W-C Ko; P-R Hsueh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-11-04       Impact factor: 3.267

Review 2.  Pharmacotherapy of Lower Respiratory Tract Infections in Elderly-Focused on Antibiotics.

Authors:  Yang Liu; Yan Zhang; Wanyu Zhao; Xiaolei Liu; Fengjuan Hu; Birong Dong
Journal:  Front Pharmacol       Date:  2019-10-31       Impact factor: 5.810

3.  Predominant role of Haemophilus influenzae in the association of conjunctivitis, acute otitis media and acute bacterial paranasal sinusitis in children.

Authors:  Ya-Li Hu; Ping-Ing Lee; Po-Ren Hsueh; Chun-Yi Lu; Luan-Yin Chang; Li-Min Huang; Tu-Hsuan Chang; Jong-Min Chen
Journal:  Sci Rep       Date:  2021-01-08       Impact factor: 4.379

4.  Fatal Meningitis and Sepsis Caused by Nontypeable Haemophilus influenzae.

Authors:  Olga M Klibanov; Heather Kehr; Zanesha Jeter; Tabugbo Ekwonu
Journal:  J Med Cases       Date:  2022-08-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.